// April 18, 2024
USP’s commitment to ESG considerations for a healthier, more sustainable world
At the U.S.
At the U.S.
Interest in innovative vaccines that use messenger ribonucleic acid (mRNA) and viral vectored tec
USP has launched the newest tool in our suite of solutions to address the evolving nitrosamines c